MarketCap
Facebook
X
Telegram
Cogent Biosciences Balance Sheet 2025-2011 | COGT
Brief balance sheet overview of Cogent Biosciences
The review uses the five latest available annual reports between 2021 and 2025.
Assets reached $937.6 million, compared with $232.1 million at the beginning. Growth of +304% and CAGR near 41.8% show active expansion.
Funding shifted toward liabilities: they gained +1,582.1%, compared with +304% for assets.
The equity ratio reached 67.9% from 92.3%. A high capital share reduces dependence on liabilities.
Net debt moved below zero to -$87.6 million, reflecting surplus cash over debt.
Cash equals 33.3% of the balance sheet, compared with 95.2% five periods ago. This is the readily available cushion.
The balance sheet carries negative retained earnings of -$1.2 billion. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
Cogent Biosciences's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Cogent Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-87.6 M | -80.7 M | -34.4 M | -120 M | -218 M | -237 M | -31.4 M | -55.7 M | -28.3 M | -41.3 M | - | - | - | - | - |
Long Term Debt |
223 M | 15.9 M | 17.5 M | 18.2 M | 831 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.55 M | 1.56 M | 1.39 M | 1.42 M | 2.32 M | 2.05 M | 1.62 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 3.16 M | 4.41 M | 748 K | 9.62 M | 14.4 M | - | - | - | - | - |
Total Current Liabilities |
64 M | 55.7 M | 38.2 M | 26.8 M | 17.1 M | 13.1 M | 13.2 M | 24.9 M | - | - | - | - | - | - | - |
Total Liabilities |
301 M | 71.6 M | 55.6 M | 45.1 M | 17.9 M | 16.2 M | 17.7 M | 25.7 M | 20.8 M | 23.2 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | 1.32 M | 17.9 M | 6.89 M | 5.96 M | - | - | - | - | - |
Retained Earnings |
-1.19 B | -859 M | -604 M | -411 M | -271 M | -199 M | -124 M | -92.1 M | -51.3 M | -25.8 M | - | - | - | - | - |
Total Assets |
938 M | 328 M | 313 M | 301 M | 232 M | 251 M | 49.4 M | 85.9 M | 49.1 M | 75.6 M | - | - | - | - | - |
Cash and Cash Equivalents |
312 M | 98.2 M | 53.2 M | 140 M | 221 M | 242 M | 37.4 M | 55.7 M | 29.6 M | - | - | - | - | - | - |
Book Value |
636 M | 256 M | 258 M | 256 M | 214 M | 235 M | 31.8 M | 60.2 M | 28.3 M | 52.4 M | - | - | - | - | - |
Total Shareholders Equity |
636 M | 256 M | 258 M | 256 M | 214 M | 235 M | 31.8 M | 60.2 M | -48.8 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Cogent Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
14.4 M | 223 M | 223 M | 44.2 M | 43.9 M | 15.5 M | 15.9 M | 16.3 M | 16.7 M | 17.1 M | 17.5 M | 17.8 M | 18.2 M | 18.5 M | 18.2 M | 18.1 M | 19 M | 1.13 M | 831 K | 1.44 M | 2.03 M | 2.6 M | 3.16 M | 3.16 M | 3.16 M | 3.16 M | 4.41 M | 4.41 M | 4.41 M | 4.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
301 M | 295 M | 301 M | 123 M | 120 M | 64.8 M | 71.6 M | 69.4 M | 56.7 M | 53.8 M | 55.6 M | 52.5 M | 43.9 M | 39.6 M | 45.1 M | 41.6 M | 46.7 M | 19 M | 17.9 M | 18.1 M | 15.7 M | 10.8 M | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 25.7 M | 25.7 M | 25.7 M | 25.7 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 312 K | 841 K | 1.32 M | 1.32 M | 1.32 M | 1.32 M | 17.9 M | 20.1 M | 20.4 M | 17.5 M | 6.89 M | - | 6.89 M | 6.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.19 B | -1.29 B | -1.19 B | -1.09 B | -1 B | -931 M | -859 M | -792 M | -721 M | -662 M | -604 M | -549 M | -494 M | -450 M | -411 M | -372 M | -337 M | -302 M | -271 M | -246 M | -227 M | -210 M | -199 M | -199 M | -199 M | -199 M | -124 M | -124 M | -124 M | -124 M | -92.1 M | -92.1 M | -92.1 M | -92.1 M | -51.3 M | -51.3 M | -51.3 M | -51.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
938 M | 903 M | 938 M | 426 M | 275 M | 284 M | 328 M | 384 M | 430 M | 476 M | 313 M | 355 M | 392 M | 263 M | 301 M | 332 M | 366 M | 207 M | 232 M | 215 M | 229 M | 238 M | 251 M | 251 M | 251 M | 251 M | 49.4 M | 49.4 M | 49.4 M | 49.4 M | 85.9 M | 85.9 M | 85.9 M | 85.9 M | 49.1 M | 49.1 M | 49.1 M | 49.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
98.2 M | 241 M | 312 M | 125 M | 128 M | 126 M | 98.2 M | 97 M | 88.2 M | 216 M | 53.2 M | 86.8 M | 214 M | 162 M | 140 M | 142 M | 327 M | 192 M | 220 M | 204 M | 219 M | 231 M | 243 M | 242 M | 242 M | 242 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 55.7 M | 55.7 M | 55.7 M | 55.7 M | 28.3 M | 28.3 M | 28.3 M | 28.3 M | 42.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
636 M | 608 M | 636 M | 302 M | 155 M | 219 M | 256 M | 315 M | 373 M | 422 M | 258 M | 303 M | 348 M | 224 M | 256 M | 290 M | 319 M | 188 M | 214 M | 197 M | 213 M | 227 M | 235 M | 235 M | 235 M | 235 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 60.2 M | 60.2 M | 60.2 M | 60.2 M | 28.3 M | 28.3 M | 28.3 M | 28.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
256 M | 608 M | 636 M | 302 M | 155 M | 219 M | 256 M | 315 M | 373 M | 422 M | 258 M | 303 M | 348 M | 224 M | 256 M | 290 M | 319 M | 188 M | 214 M | 197 M | 213 M | 227 M | 235 M | 235 M | 235 M | 235 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 60.2 M | 60.2 M | 60.2 M | 60.2 M | -48.8 M | -48.8 M | -48.8 M | -48.8 M | -24.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Cogent Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Russia
China
Curacao
Israel
